American Association Of Clinical Endocrinologists And American College Of Endocrinology 2016 Outpatient Glucose Monitoring Consensus Statement

Assessment of Medication Adherence in Type II Diabetic Patients: A Cross-sectional Study

“…2,3 In recent years, newer antidiabetic drugs have been introduced to optimally control diabetes, which have increased the complexity of diabetes treatment algorithms leading to multiple second-line and third-line options. [4][5][6][7] Nonadherence to medication declines the efficacy of the medication and, in turn, the glycemic control. 8 Adherence is referred as active, voluntary, and collaborative involvement of the patient in a mutually acceptable course of behavior to produce a therapeutic result.…”

Improving the Clinical Value and Utility of CGM Systems: Issues and Recommendations

“…Although this suggests that the field is coming of age, review of the existing evidence base has generated diverse conclusions, ranging from "limited evidence" (Cochrane review) (25) to fully supportive (28)(29)(30). In only two of the meta-analyses have individual patientlevel data been combined: both of these showed a small improvement in HbA 1c with no change in rates of hypoglycemia (4,28). The others used mean values and took different approaches to inclusion and exclusion criteria, pooled data from CGM systems with different performance characteristics, and/or focused on studies financed by particular manufacturers (27) [3b].…”

Clinical Use of Continuous Glucose Monitoring in Pediatrics

“…25 Multiple professional organizations have attempted to provide recommendations based on these numerous studies with data spanning well over a decade (Table 1). [26][27][28] One goal of accurate CGM is to inform control systems that modulate insulin delivery using a mechanical pump. The 2010 Sensor Augmented Pump Therapy for A1c Reduction (STAR3) study involved a 1-year, multicenter randomized controlled trial among 156 children (age 7-18 years) and 329 adults with type 1 diabetes and suboptimal control (HbA1c 7.4%-9.5%).…”